Literature DB >> 19894656

Definition of hypertension: the impact of number of visits for blood pressure measurement.

Daniela Figueiredo1, Ana Azevedo, Marta Pereira, Henrique de Barros.   

Abstract

INTRODUCTION: A diagnosis of hypertension should be based on multiple blood pressure (BP) measurements, taken on at least two separate occasions. We aimed to assess the impact of considering different criteria for a definition of hypertension, based on number of visits for blood pressure measurement, on estimates of hypertension prevalence, awareness, treatment and control, and on its association with two variables definitely related to hypertension: body mass index and left ventricular hypertrophy.
METHODS: We used data from a cross-sectional study of 739 participants, aged > or = 45 years, randomly selected from a non-institutionalized Portuguese population, from January 2001 to December 2003. Main outcome measures were prevalence of hypertension (systolic BP > or = 140 mmHg and/or diastolic BP > or = 90 mmHg or current antihypertensive drug therapy) based on BP measurements on one visit, on BP measurements on a second visit or on fulfilling the same criteria on the two different visits.
RESULTS: Estimated hypertension prevalence was 63.4% (95% CI: 59.8-66.9) using BP measurements from the first visit (HTN1) and 60.2% (95% CI: 56.6-63.8) using BP measurements from the second visit (HTN2). If both visits are used as criteria the estimated hypertension prevalence (HTN(Final)) was 56.3% (95% CI: 52.7-60.0), p (McNemar test) < 0.001, between HTN1 and HTN(Final) and between HTN2 and HTN(Final). Awareness, treatment and control changed from 60.2% to 64.4%, 53.1% to 59.8% and 24.9% to 22.0%, respectively, when using information from the first or both visits. All three different estimates of hypertension prevalence have a similar strong and independent association with body mass index (OR = 2.71 for body mass index > or = 30 with HTN(Final)) and with left ventricular hypertrophy (OR = 3.21 for HTN(Final) with left ventricular hypertrophy). DISCUSSION AND
CONCLUSIONS: In many individuals labeled as hypertensive on a single evaluation, hypertension was not confirmed on reassessment, leading to a significant overestimation of 12.6% of the true prevalence. For this reason BP should be measured on at least two office visits both for clinical purposes and in epidemiological studies. On the other hand, this did not reflect on the association between hypertension and body mass index or left ventricular hypertrophy, suggesting that unconfirmed cases do not necessarily imply misclassification.

Entities:  

Mesh:

Year:  2009        PMID: 19894656

Source DB:  PubMed          Journal:  Rev Port Cardiol        ISSN: 0870-2551            Impact factor:   1.374


  16 in total

Review 1.  Definition of pediatric hypertension: are blood pressure measurements on three separate occasions necessary?

Authors:  Jiahong Sun; Lyn M Steffen; Chuanwei Ma; Yajun Liang; Bo Xi
Journal:  Hypertens Res       Date:  2017-01-12       Impact factor: 3.872

2.  Prevalence of childhood hypertension and hypertension phenotypes by weight status and waist circumference: the Healthy Growth Study.

Authors:  Yannis Manios; K Karatzi; A D Protogerou; G Moschonis; C Tsirimiagou; O Androutsos; C Lionis; G P Chrousos
Journal:  Eur J Nutr       Date:  2017-03-27       Impact factor: 5.614

3.  Impact of single-visit American versus European office blood pressure measurement procedure on individual blood pressure classification: a cross-sectional study.

Authors:  Annina S Vischer; Thenral Socrates; Clemens Winterhalder; Jens Eckstein; Michael Mayr; Thilo Burkard
Journal:  Clin Res Cardiol       Date:  2019-02-06       Impact factor: 5.460

4.  Incarceration History and Uncontrolled Blood Pressure in a Multi-Site Cohort.

Authors:  Benjamin A Howell; Jessica B Long; E Jennifer Edelman; Kathleen A McGinnis; David Rimland; David A Fiellin; Amy C Justice; Emily A Wang
Journal:  J Gen Intern Med       Date:  2016-09-12       Impact factor: 5.128

5.  An epidemiological study determining blood pressure in a Portuguese cohort: the Guimarães/Vizela study.

Authors:  P G Cunha; J Cotter; P Oliveira; I Vila; N Sousa
Journal:  J Hum Hypertens       Date:  2014-07-31       Impact factor: 3.012

6.  From the Epidemiologist to the Physician: A Complex Issue for a Labile Risk.

Authors:  Pietro Amedeo Modesti; Stefano Rapi
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-02-18       Impact factor: 3.738

7.  Impact of one or two visits strategy on hypertension burden estimation in HYDY, a population-based cross-sectional study: implications for healthcare resource allocation decision making.

Authors:  Pietro Amedeo Modesti; Stefano Rapi; Mohamed Bamoshmoosh; Marzia Baldereschi; Luciano Massetti; Luigi Padeletti; Gian Franco Gensini; Dong Zhao; Dawood Al-Hidabi; Husni Al Goshae
Journal:  BMJ Open       Date:  2012-08-08       Impact factor: 2.692

8.  Development of a risk prediction model for incident hypertension in Japanese individuals: the Hisayama Study.

Authors:  Emi Oishi; Jun Hata; Takanori Honda; Satoko Sakata; Sanmei Chen; Yoichiro Hirakawa; Daigo Yoshida; Mao Shibata; Tomoyuki Ohara; Yoshihiko Furuta; Takanari Kitazono; Toshiharu Ninomiya
Journal:  Hypertens Res       Date:  2021-05-31       Impact factor: 3.872

Review 9.  Need for better blood pressure measurement in developing countries to improve prevention of cardiovascular disease.

Authors:  Pietro Amedeo Modesti; Eleonora Perruolo; Gianfranco Parati
Journal:  J Epidemiol       Date:  2014-11-22       Impact factor: 3.211

10.  Cardiovascular risk assessment in low-resource settings: a consensus document of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk in Low Resource Settings.

Authors:  Pietro A Modesti; Piergiuseppe Agostoni; Charles Agyemang; Sanjay Basu; Athanase Benetos; Francesco P Cappuccio; Antonio Ceriello; Stefano Del Prato; Robert Kalyesubula; Eoin O'Brien; Michael O Kilama; Stefano Perlini; Eugenio Picano; Gianpaolo Reboldi; Giuseppe Remuzzi; David Stuckler; Marc Twagirumukiza; Luc M Van Bortel; Ghassan Watfa; Dong Zhao; Gianfranco Parati
Journal:  J Hypertens       Date:  2014-05       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.